Literature DB >> 12784111

The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones.

Carmine M Pariante1, Abdul Hye, Ritchie Williamson, Andrew Makoff, Simon Lovestone, Robert W Kerwin.   

Abstract

Incubation of LMCAT fibroblasts cells with antidepressants potentiates glucocorticoid receptor (GR)-mediated gene transcription in the presence of cortisol, but not of corticosterone. We have suggested that antidepressants do so by inhibiting the LMCAT cells membrane steroid transporter and thus by increasing cortisol intracellular concentrations. We now confirm and extend this model to primary neuronal cultures. Clomipramine, a tricyclic antidepressant, increased the intracellular accumulation of 3H-cortisol, but not 3H-corticosterone, in LMCAT cells (+80%) and primary rat neurones (+20%). The latter finding is the first demonstration that a membrane steroid transporter is present in neurones. Moreover, verapamil, a membrane steroid transporter inhibitor, reduced the effects of clomipramine on the intracellular accumulation of 3H-cortisol in LMCAT cells. Finally, clomipramine also decreased GR expression (whole-cell Western blot) in LMCAT cells (50% reduction) and primary rat neurones (80% reduction). This GR downregulation can explain the reduced GR-mediated gene transcription previously described under experimental conditions that do not elicit the effects on the LMCAT cells steroid transporter. This work further supports the hypothesis that membrane steroid transporters regulating the access of glucocorticoids to the brain in vivo are a fundamental target for antidepressant action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784111     DOI: 10.1038/sj.npp.1300195

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  21 in total

1.  Clomipramine in vitro reduces glucocorticoid receptor function in healthy subjects but not in patients with major depression.

Authors:  Livia A Carvalho; Mario F Juruena; Andrew S Papadopoulos; Lucia Poon; Rob Kerwin; Anthony J Cleare; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2008-03-26       Impact factor: 7.853

Review 2.  Neuroplasticity and major depression, the role of modern antidepressant drugs.

Authors:  Gianluca Serafini
Journal:  World J Psychiatry       Date:  2012-06-22

Review 3.  The glucocorticoid receptor: pivot of depression and of antidepressant treatment?

Authors:  Christoph Anacker; Patricia A Zunszain; Livia A Carvalho; Carmine M Pariante
Journal:  Psychoneuroendocrinology       Date:  2011-04       Impact factor: 4.905

4.  Chronic non-invasive corticosterone administration abolishes the diurnal pattern of tph2 expression.

Authors:  Nina C Donner; Christian D Montoya; Jodi L Lukkes; Christopher A Lowry
Journal:  Psychoneuroendocrinology       Date:  2011-09-15       Impact factor: 4.905

Review 5.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

6.  Activation of cAMP-protein kinase A abrogates STAT5-mediated inhibition of glucocorticoid receptor signaling by interferon-alpha.

Authors:  Thaddeus W W Pace; Fang Hu; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2011-07-21       Impact factor: 7.217

Review 7.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

8.  Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters.

Authors:  Carmine M Pariante; Richard B Kim; Andrew Makoff; Robert W Kerwin
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

9.  Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers.

Authors:  Carmine M Pariante; Andrew S Papadopoulos; Lucia Poon; Anthony J Cleare; Stuart A Checkley; Judie English; Robert W Kerwin; Stafford Lightman
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

Review 10.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.